Literature DB >> 16462517

Malignancy and autoimmunity.

Sasha Bernatsky1, Rosalind Ramsey-Goldman, Ann Clarke.   

Abstract

PURPOSE OF REVIEW: The association of cancer with autoimmune disease has been under investigation for several years. Reports have appeared suggesting increased cancer risk in autoimmune rheumatic diseases. Evidence has been accumulating recently in rheumatoid arthritis, Sjogren's syndrome, systemic lupus erythematosus, and scleroderma/systemic sclerosis. This review focuses on recent publications regarding risk of cancer in these conditions. RECENT
FINDINGS: Despite a lack of a strong association between rheumatoid arthritis and cancer overall, studies show an increased risk for the development of lymphoma in rheumatoid arthritis. There are data suggesting an increased risk for rheumatoid arthritis patients regarding lung cancer. In Sjogren's syndrome-related malignancies, most publications in the past year relate to non-Hodgkin's lymphomas, and suggest possible mechanisms driving the association. Data substantiate an increased risk of certain cancers in systemic lupus erythematosus; the risk appears to be most heightened for lymphoma. A recent cohort study examined cancer risk in scleroderma; the estimates were lower than previous studies had suggested, and the confidence intervals relatively imprecise, making a definitive conclusion difficult.
SUMMARY: There have been several papers published related to cancer in the rheumatic diseases, particularly inflammatory arthritis, Sjogren's syndrome, systemic lupus erythematosus, and scleroderma/systemic sclerosis. Continuing interest in the association between autoimmune rheumatic diseases and malignancy is likely, given the potential impact in terms of understanding both rheumatic diseases and cancer.

Entities:  

Mesh:

Year:  2006        PMID: 16462517     DOI: 10.1097/01.bor.0000209423.39033.94

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  29 in total

1.  Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis.

Authors:  Kenan Aksu; Ayhan Donmez; Yesim Ertan; Gokhan Keser; Vedat Inal; Gonca Oder; Murat Tombuloglu; Yasemin Kabasakal; Eker Doganavsargil
Journal:  Rheumatol Int       Date:  2007-07-11       Impact factor: 2.631

2.  Autoimmunity and Cancer, the Paradox Comorbidities Challenging Therapy in the Context of Preexisting Autoimmunity.

Authors:  Julio C Valencia; Nkolika Egbukichi; Rebecca A Erwin-Cohen
Journal:  J Interferon Cytokine Res       Date:  2018-12-18       Impact factor: 2.607

3.  A role for human endogenous retrovirus-K (HML-2) in rheumatoid arthritis: investigating mechanisms of pathogenesis.

Authors:  G Freimanis; P Hooley; H Davari Ejtehadi; H A Ali; A Veitch; P B Rylance; A Alawi; J Axford; A Nevill; P G Murray; P N Nelson
Journal:  Clin Exp Immunol       Date:  2010-03-16       Impact factor: 4.330

4.  Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer Vaccines.

Authors:  Adam Yagui-Beltrán; Lisa M Coussens; David M Jablons
Journal:  US Oncol       Date:  2009

5.  The age-risk relationship of hematologic malignancies in patients with rheumatoid arthritis: a nationwide retrospective cohort study.

Authors:  Yu-Chih Lin; Hui-Wen Chou; Wen-Chan Tsai; Jeng-Hsien Yen; Shun-Jen Chang; Yi-Ching Lin
Journal:  Clin Rheumatol       Date:  2015-05-20       Impact factor: 2.980

6.  Thyroid nodules and cancer in children and adolescents affected by Hashimoto's thyroiditis.

Authors:  Ji Hye Won; Ji Ye Lee; Hyun Sook Hong; Sun Hye Jeong
Journal:  Br J Radiol       Date:  2018-04-09       Impact factor: 3.039

7.  [Rationale for bone marrow examination in patients with inflammatory rheumatic diseases].

Authors:  Jutta G Richter; Pascal Gossen; Ulrich Germing; Sabine Blum; Barbara Hildebrandt; Stefan Braunstein; Dörte Huscher; Matthias Schneider
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

Review 8.  Perception of self: distinguishing autoimmunity from autoinflammation.

Authors:  Tessa S van Kempen; Mark H Wenink; Emmerik F A Leijten; Timothy R D J Radstake; Marianne Boes
Journal:  Nat Rev Rheumatol       Date:  2015-05-12       Impact factor: 20.543

Review 9.  B cells and their mediators as targets for therapy in solid tumors.

Authors:  Andrew J Gunderson; Lisa M Coussens
Journal:  Exp Cell Res       Date:  2013-03-13       Impact factor: 3.905

10.  Non-Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis.

Authors:  Kenan Aksu; Seckin Cagirgan; Nazan Ozsan; Gokhan Keser; Fahri Sahin
Journal:  Rheumatol Int       Date:  2009-12-16       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.